Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rheopheresis for Raynaud's in Systemic Sclerosis
NCT05204784Unknown
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, open-label trial (3 arms). Primary endpoint: Raynaud Condition Score at 24 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT05204784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204784.